Podcast: Advancing Research in the World of Prebiotics

Whether you prefer yogurt, kimchi, kefir, or kombucha, probiotics are all around us. But how do we really harness the benefits of this good bacteria, and capitalize on consuming foods that keep us healthy? The answer — Prebiotics.

Tackling the science, consumer habits, and marketing behind prebiotics in this episode of the MarketScale Sciences Podcast are scientists John Davidson, Director of Innovation & Education for Deerland Probioics & Enzymes, and John Deaton, VP of Science & Technology for Deerland Probiotics & Enzymes. This episode talks about how and why it is important to prime your gut with prebiotics, in order to truly harness the power of probiotics. From a marketing standpoint “probiotics were first out of the gate,” Deaton says, “but it’s not as simple as consuming a probiotic.”

Probiotic organisms are not very shelf-stable, nor very resilient to our stomach acids. This is why a prebiotic is so important. As non-living organisms, prebiotics are a food source or a compound, and much easier to manage in application. But, for real efficacy, prebiotics must be consumed in large doses. Herein lies the crux that is being tackled head-on.

How do we provide a prebiotic that is small, consumable, and reduces the main side effect of gas, caused by fermentation in the gut? Listen to the podcast above to learn more.

Investing in Science: The Future of Supplements

Consumer demand is driving production for probiotic solutions as new technologies and more information become available regarding the importance of gut health. Previously, the achilles heel of the supplement industry has often been the lack of  scientific evidence to support claims.

Initiatives such as the Human Microbiome Project, a worldwide initiative that’s attempting to map out the entire microbiome, has helped to increase education and understanding of the microbiome’s impact on health.

Listen in to learn how the current marketplace for supplements is changing, how consumer demand impacts this, and why clinical studies are the most difficult-to-surpass but most necessary barrier to entry.